1-(Tetrahydropyran-4-yl)piperazine

Catalog No.: 
ACCHIG148
CAS No.: 
398137-19-4
Molecular Formula: 
C9H18N2O
Molecular Weight: 
170.26
1-(Tetrahydropyran-4-yl)piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$59.00InquiryInquiry
1g98%$151.00InquiryInquiry
5g98%$454.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(Tetrahydropyran-4-yl)piperazine
IUPAC Name1-(tetrahydro-2H-pyran-4-yl)piperazine
MDL No.MFCD11043433
Molecular FormulaC9H18N2O
Molecular Weight170.26
SMILESN1(C2CCOCC2)CCNCC1
InChI KeyGWNSHRCBWQEQPK-UHFFFAOYSA-N
SynonymPiperazine,1-(tetrahydro-2H-pyran-4-yl)-(9CI);1-(TETRAHYDRO-2H-PYRAN-4-YL)PIPERAZINE;1-(tetrahydro-2H-pyran-4-yl)piperazine(SALTDATA: 2HCl 0.5H2O);1-(Tetrahydro-pyran-4-yl)-piperazine;1-(Oxan-4-yl)piperazine;Piperazine, 1-(tetrahydro-2H-pyran-4-yl)-;1-(oxepan-4-yl)piperazine
CAS No.398137-19-4
PubChem CID21942315

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACCHIG148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPYCL530 route compound structure diagram
    ACPYCL530120-43-4In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCHIG148 route product structure diagram
    ACCHIG148398137-19-4
Inquiry

2. ACCHIG148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCHIG148 route product structure diagram
    ACCHIG148398137-19-4
Inquiry

3. ACCHIG148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCHIG148 route product structure diagram
    ACCHIG148398137-19-4
Inquiry

Comments (0)